Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment

Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits

INDIANAPOLIS, August 04, 2025: Eli Lilly and Company (NYSE: LLY) announcedresults from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showingthat participants treated with Kisunla (donanemab-azbt)demonstrated slowing of decline, a benefitthat continued to grow over threeyears compared to an untreated external cohort from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).